Patent application number | Description | Published |
20080213233 | Method of Delivering Nucleic Acid Molecules Into Embryonic Stem Cells Using Baculoviral Vectors - There is provided a method of delivering a nucleic acid molecule to an embryonic stem cell, including a human embryonic stem cell, by infecting the embryonic stem cell with a baculoviral vector comprising the nucleic acid molecule. Embryonic stem cells transduced by this method are useful for treating a disease or disorder in a subject. | 09-04-2008 |
20080318882 | Method of Delivery of Nucleic Acids to Peripheral Neurons - The invention provides for methods for delivering a nucleic acid into a peripheral neuron by identifying a target neuron in a dorsal root ganglion and intrathecally delivering a vector comprising the nucleic acid to the dorsal root ganglion neuron. The nucleic acid may encode a neurotrophic factor that may be used to treat a peripheral neuropathy or, in conjunction with a nerve guide conduit, to treat a transected peripheral nerve. | 12-25-2008 |
20090041665 | METHOD FOR GENE DELIVERY TO NEURONAL CELLS - The present invention relates to the use of axonal transport to deliver a baculovirus vector to a target neuronal cell by administering the vector to a site that is remote from the target cell. Such delivery allows for tracing of neuronal pathways and further a baculovirus vector may be used to deliver therapeutic gene to a target neuronal which may otherwise be not readily accessible, for the treatment of a neuronal disorder in a subject. | 02-12-2009 |
20090055941 | Novel Neural Cell Specific Promoter And Baculovirus And Method For Gene Delivery - There is provided a novel hybrid promoter region that utilizes a neural specific promoter and an enhancer element, in one embodiment from a viral promoter, located upstream or downstream of the neural-specific promoter. The novel promoter can be used to create a viral vector, including a baculovirus vector, useful for gene delivery to neural cells. | 02-26-2009 |
20100111913 | METHOD OF ENHANCING MIGRATION OF NEURAL PRECURSOR CELLS - There is provided methods relating to enhancing migration of a neural precursor cell by augmenting levels of TMEM18 protein in the neural precursor cell. Such methods may be used in the treatment of disorders, including treatment of a glioma or a neurodegenerative disorder. | 05-06-2010 |
20110098346 | NUCLEIC ACID MOLECULE AND METHOD OF TARGETING GENE EXPRESSION TO GLIOMAS - There is presently provided a nucleic acid molecule comprising a glial-specific promoter; a coding sequence for a transgene; and a plurality of miRNA target sites. Each miRNA target site binds an miRNA that is down-regulated in .a glioma cell compared to a normal glial cell, and the glial-specific promoter and the plurality of miRNA target sites are both operably linked to the coding sequence for the transgene. | 04-28-2011 |
20130344095 | METHOD OF USING CD1D OVER-EXPRESSION IN HUMAN DENDRITIC CELLS TO ENHANCE CD8+ T CELL-BASED AND INVARIANT NATURAL KILLER T CELL-BASED ANTITUMOR IMMUNITY - The manipulation of human dendritic cells (DCs) to induce potent anti-tumor immunity remains an essential subject of study. Here we report that the overexpression of CD1d in human DCs can enhance the priming of naïve CD8+ T cells against tumor antigen. We showed that CD1d can be overexpressed in the human DCs using baculoviral vector carrying the CD1d gene. This CD1d-overexpression is functional as demonstrated by the increased expansion of invariant natural killer T (iNKT) cells while using these modified DCs to present α-galactosylceramide (α-GC). Pulsed with tumor antigenic peptide, these CD1d-overexpressing human DCs showed enhanced capability to prime naïve CD8+ T cells. CD1d-overexpressing human DCs also induced a pro-inflammatory cytokine profile that may favor the priming. Moreover, this CD1d-overexpression strategy can be extrapolated to monocyte-derived human DCs. Therefore, our study suggest that overexpression of CD1d in human DCs may provide a novel strategy to enhance DC immunogenicity and the possible translation into human cancer immunotherapy. | 12-26-2013 |
20150197773 | METHODS FOR BLADDER CANCER THERAPY USING BACULOVIRAL VECTORS - There is presently provided methods and uses relating to delivering a nucleic acid molecule to a bladder cell using a baculoviral vector. The bladder cell is contacted with a baculoviral vector, which may further comprise a transgene. | 07-16-2015 |